Characteristics of 183 patients with thrombocytosis
. | Essential thrombocythemia . | Reactive thrombocytosis . |
---|---|---|
No. patients | 164 | 19 |
Cause of thrombocytosis | ET (n = 164) | Inflammatory disorder (n = 8) |
Lymphoma (n = 5) | ||
Iron deficiency (n = 2) | ||
Malignancy (n = 2) | ||
Liver disease (n = 2) | ||
Sex | ||
Male | 63 (38.4%) | 10 (52.6%) |
Female | 101 (61.6%) | 9 (47.4%) |
Age at diagnosis, median (y) | 63.2 (range, 12-91.7) | NA |
Age at bone marrow study, median (y) | 64.9 (range, 18-91.7) | 54.6 (range, 2.5-74.8) |
Duration of follow-up from diagnosis, median (mo) | 71.6 (range, 0.03-403) | NA |
Duration of follow-up from bone marrow study, median (mo) | 58.9 (range, 0-148) | 9 (1-98) |
Interval, diagnosis to bone marrow study, median (mo) | 0 (range, 0-397) | NA |
< 3 mos from diagnosis | 113 (68.9%) | NA |
Status at last follow-up | ||
Alive | 128 (78.0%) | 17 (89.5%) |
Deceased | 36 (22.0%) | 2 (10.5%) |
Cause of death | 5 ET related (3.0%) | NA |
Chemotherapy naive at time of bone marrow study | 127 (77.4%) | NA |
Laboratory values/examinations at diagnosis, median (range) | ||
Hemoglobin (g/dL) | 13.7 (8.7-17.3) | NA |
Leukocyte count (× 109/L) | 9.5 (1.3-45.4) | — |
Platelet count (× 109/L) | 976 (404-2525) | — |
Palpable spleen | 33 (20.1%) | — |
Palpable liver | 6 (3.7%) | — |
Laboratory values/examinations at bone marrow study, median (range) | ||
Hemoglobin (g/dL) | 13.6 (8.4-17.3) | 10.3 (8.5-13.3) |
Leukocyte count (× 109/L) | 8.9 (1.3-45.4) | 11 (6.7-24.4) |
Platelet count (× 109/L) | 930 (144-2525) | 643 (500-1103) |
Palpable spleen | 34 (20.7%) | 0 |
Palpable liver | 6 (3.7%) | 0 |
Vascular event (? yes) | 63 (38.4%) | 0 |
Number of vascular events | ||
0 | 104 (63.4%) | NA |
1 | 53 (32.3%) | — |
2 | 8 (4.9%) | — |
3 | 2 (1.2%) | — |
Type of vascular event | ||
Thrombosis | 44 (69.8%) | NA |
Bleeding | 19 (30.2%) | — |
Labs at first vascular event, median (range) | ||
Hemoglobin (g/dL) | 13.6 (9.3-16.4) | NA |
Leukocyte count (× 109/L) | 11.5 (3.6-45) | — |
Platelet count (× 109/L) | 920 (151-2620) | — |
. | Essential thrombocythemia . | Reactive thrombocytosis . |
---|---|---|
No. patients | 164 | 19 |
Cause of thrombocytosis | ET (n = 164) | Inflammatory disorder (n = 8) |
Lymphoma (n = 5) | ||
Iron deficiency (n = 2) | ||
Malignancy (n = 2) | ||
Liver disease (n = 2) | ||
Sex | ||
Male | 63 (38.4%) | 10 (52.6%) |
Female | 101 (61.6%) | 9 (47.4%) |
Age at diagnosis, median (y) | 63.2 (range, 12-91.7) | NA |
Age at bone marrow study, median (y) | 64.9 (range, 18-91.7) | 54.6 (range, 2.5-74.8) |
Duration of follow-up from diagnosis, median (mo) | 71.6 (range, 0.03-403) | NA |
Duration of follow-up from bone marrow study, median (mo) | 58.9 (range, 0-148) | 9 (1-98) |
Interval, diagnosis to bone marrow study, median (mo) | 0 (range, 0-397) | NA |
< 3 mos from diagnosis | 113 (68.9%) | NA |
Status at last follow-up | ||
Alive | 128 (78.0%) | 17 (89.5%) |
Deceased | 36 (22.0%) | 2 (10.5%) |
Cause of death | 5 ET related (3.0%) | NA |
Chemotherapy naive at time of bone marrow study | 127 (77.4%) | NA |
Laboratory values/examinations at diagnosis, median (range) | ||
Hemoglobin (g/dL) | 13.7 (8.7-17.3) | NA |
Leukocyte count (× 109/L) | 9.5 (1.3-45.4) | — |
Platelet count (× 109/L) | 976 (404-2525) | — |
Palpable spleen | 33 (20.1%) | — |
Palpable liver | 6 (3.7%) | — |
Laboratory values/examinations at bone marrow study, median (range) | ||
Hemoglobin (g/dL) | 13.6 (8.4-17.3) | 10.3 (8.5-13.3) |
Leukocyte count (× 109/L) | 8.9 (1.3-45.4) | 11 (6.7-24.4) |
Platelet count (× 109/L) | 930 (144-2525) | 643 (500-1103) |
Palpable spleen | 34 (20.7%) | 0 |
Palpable liver | 6 (3.7%) | 0 |
Vascular event (? yes) | 63 (38.4%) | 0 |
Number of vascular events | ||
0 | 104 (63.4%) | NA |
1 | 53 (32.3%) | — |
2 | 8 (4.9%) | — |
3 | 2 (1.2%) | — |
Type of vascular event | ||
Thrombosis | 44 (69.8%) | NA |
Bleeding | 19 (30.2%) | — |
Labs at first vascular event, median (range) | ||
Hemoglobin (g/dL) | 13.6 (9.3-16.4) | NA |
Leukocyte count (× 109/L) | 11.5 (3.6-45) | — |
Platelet count (× 109/L) | 920 (151-2620) | — |
NA indicates not available.